Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient

In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Caeyman, Aaron, Vandekerckhove, Olivia, Pat, Karin, Wynants, Jokke, Weytjens, Karolien, de Wergifosse, Isabelle, Cuppens, Kristof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601759/
https://www.ncbi.nlm.nih.gov/pubmed/37900791
http://dx.doi.org/10.1159/000532098
_version_ 1785126258677383168
author Caeyman, Aaron
Vandekerckhove, Olivia
Pat, Karin
Wynants, Jokke
Weytjens, Karolien
de Wergifosse, Isabelle
Cuppens, Kristof
author_facet Caeyman, Aaron
Vandekerckhove, Olivia
Pat, Karin
Wynants, Jokke
Weytjens, Karolien
de Wergifosse, Isabelle
Cuppens, Kristof
author_sort Caeyman, Aaron
collection PubMed
description In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab).
format Online
Article
Text
id pubmed-10601759
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-106017592023-10-27 Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient Caeyman, Aaron Vandekerckhove, Olivia Pat, Karin Wynants, Jokke Weytjens, Karolien de Wergifosse, Isabelle Cuppens, Kristof Case Rep Oncol Case Report In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab). S. Karger AG 2023-10-11 /pmc/articles/PMC10601759/ /pubmed/37900791 http://dx.doi.org/10.1159/000532098 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Caeyman, Aaron
Vandekerckhove, Olivia
Pat, Karin
Wynants, Jokke
Weytjens, Karolien
de Wergifosse, Isabelle
Cuppens, Kristof
Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
title Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
title_full Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
title_fullStr Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
title_full_unstemmed Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
title_short Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
title_sort sjögren’s syndrome caused by pd-1 inhibition in a lung cancer patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601759/
https://www.ncbi.nlm.nih.gov/pubmed/37900791
http://dx.doi.org/10.1159/000532098
work_keys_str_mv AT caeymanaaron sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient
AT vandekerckhoveolivia sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient
AT patkarin sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient
AT wynantsjokke sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient
AT weytjenskarolien sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient
AT dewergifosseisabelle sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient
AT cuppenskristof sjogrenssyndromecausedbypd1inhibitioninalungcancerpatient

Ejemplares similares